Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Novel Phase I/IIa Open Label Study of IMM 101 in Combination With Selected Standard of Care (SOC) Regimens in Patients With Metastatic Cancer or Unresectable Cancer at Study Entry

NCT03009058 is registered in ClinicalTrials.gov with Immodulon Therapeutics Ltd as lead sponsor.

NCT NCT03009058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03009058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Novel Phase I/IIa Open Label Study of IMM 101 in Combination With Selected Standard of Care (SOC) Regimens in Patients With Metastatic Cancer or Unresectable Cancer at Study Entry
Lead sponsor
Immodulon Therapeutics Ltd
Phase
Phase 1/2
Overall status
Terminated
Start date
May 31, 2017
Completion date
August 30, 2017
Enrollment
2 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic cancer